Fig. 2: NKG2A and PD-1/PD-L1 axis immune checkpoint blockade improves the therapeutic outcome of ATRi/RT.

Experiments in this figure were performed in the MOC1 model. A Tumour growth and survival curves across the different conditions (Control n = 10, ATRi n = 11, RT n = 11, ATRi/RT n = 11; combined from two independent experiments). B Bar chart; % of NKG2A and/or PD-1 positive populations in CD8 and CD4_conv T cells, scatter plot with bar; NKG2A/PD-1 positive populations in CD8 and CD4_conv T cells (Control n = 8, ATRi/RT n = 12; combined from two independent experiments). C Heatmap showing marker intensity of expression in NKG2A⁺/PD-1⁺ versus NKG2A⁻/PD-1⁻ CD8 and CD4_conv T cells. D % surface expression of Qa-1b/PD-L1 double positive cancer cells in the different conditions (Control n = 8, ATRi/RT n = 8; from one experiment). Tumour growth and survival curves across the different conditions in ectopic (E; control n = 17, αNKG2A/αPD-L1 n = 17, ATRi/RT n = 16, ATRi/RT/αPD-L1 n = 12, ATRi/RT/αNKG2A/αPD-L1 n = 17; combined from three independent experiments) and orthotopic (F; Control n = 8, αNKG2A/αPD-L1 n = 5, ATRi/RT n = 10, ATRi/RT/αPD-L1 n = 6, ATRi/RT/αNKG2A/αPD-L1 n = 12; combined from two independent experiments). G Tumour growth in control versus rechallenged mice (Rechallenge n = 5, Control n = 6; from one experiment). Results are shown as means ± SEM and n represents number of mouse/groups. Parametric statistics were only applied to normally distributed data. Numbers on graphs represent P values and were determined by Two-tailed Unpaired t test (A, CD4conv T cells and D), Two-tailed Mann–Whitney test (A, CD8 T cells) and Log-Rank Mantel–Cox test (C, E, F).